Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
ImportanceCancer was a common noncommunicable disease in Syria before the present conflict and is now a major disease burden among 3.6 million Syrian refugees in Turkey. Data to inform health care practice are needed.ObjectiveTo explore sociodemographic characteristics, clinical characteristics, and treatment outcomes of Syrian patients with cancer residing in the southern border provinces of Turkey hosting more than 50% of refugees.Design, Setting, and ParticipantsThis was a retrospective hospital-based cross-sectional study. The study sample consisted of all adult and children Syrian refugees diagnosed and/or treated for cancer between January 1, 2011, and December 31, 2020, in hematology-oncology departments of 8 university hospitals in the Southern province of Turkey. Data were analyzed from May 1, 2022, to September 30, 2022.Main Outcomes and MeasuresDemographic characteristics (date of birth, sex, and residence), date of first cancer-related symptom, date and place of diagnosis, disease status at first presentation, treatment modalities, date and status at last hospital visit, and date of death. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision and International Classification of Childhood Cancers, Third Edition, were used for the classification of cancer. The Surveillance, Epidemiology, and End Results system was applied for staging. The diagnostic interval was defined as the number of days from first symptoms until the diagnosis. Treatment abandonment was documented if the patient did not attend the clinic within 4 weeks of a prescribed appointment throughout the treatment.ResultsA total of 1114 Syrian adult and 421 Syrian children with cancer were included. The median age at diagnosis was 48.2 (IQR, 34.2-59.4) years for adults and 5.7 (IQR, 3.1-10.7) years for children. The median diagnostic interval was 66 (IQR, 26.5-114.3) days for adults and 28 (IQR, 14.0-69.0) days for children. Breast cancer (154 [13.8%]), leukemia and multiple myeloma (147 [13.2%]), and lymphoma (141 [12.7%]) were common among adults, and leukemias (180 [42.8%]), lymphomas (66 [15.7%]), and central nervous system neoplasms (40 [9.5%]) were common among children. The median follow-up time was 37.5 (IQR, 32.6-42.3) months for adults and 25.4 (IQR, 20.9-29.9) months for children. The 5-year survival rate was 17.5% in adults and 29.7% in children.Conclusions and RelevanceDespite universal health coverage and investment in the health care system, low survival rates were reported in this study for both adults and children with cancer. These findings suggest that cancer care in refugees requires novel planning within national cancer control programs with global cooperation.
ImportanceCancer was a common noncommunicable disease in Syria before the present conflict and is now a major disease burden among 3.6 million Syrian refugees in Turkey. Data to inform health care practice are needed.ObjectiveTo explore sociodemographic characteristics, clinical characteristics, and treatment outcomes of Syrian patients with cancer residing in the southern border provinces of Turkey hosting more than 50% of refugees.Design, Setting, and ParticipantsThis was a retrospective hospital-based cross-sectional study. The study sample consisted of all adult and children Syrian refugees diagnosed and/or treated for cancer between January 1, 2011, and December 31, 2020, in hematology-oncology departments of 8 university hospitals in the Southern province of Turkey. Data were analyzed from May 1, 2022, to September 30, 2022.Main Outcomes and MeasuresDemographic characteristics (date of birth, sex, and residence), date of first cancer-related symptom, date and place of diagnosis, disease status at first presentation, treatment modalities, date and status at last hospital visit, and date of death. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision and International Classification of Childhood Cancers, Third Edition, were used for the classification of cancer. The Surveillance, Epidemiology, and End Results system was applied for staging. The diagnostic interval was defined as the number of days from first symptoms until the diagnosis. Treatment abandonment was documented if the patient did not attend the clinic within 4 weeks of a prescribed appointment throughout the treatment.ResultsA total of 1114 Syrian adult and 421 Syrian children with cancer were included. The median age at diagnosis was 48.2 (IQR, 34.2-59.4) years for adults and 5.7 (IQR, 3.1-10.7) years for children. The median diagnostic interval was 66 (IQR, 26.5-114.3) days for adults and 28 (IQR, 14.0-69.0) days for children. Breast cancer (154 [13.8%]), leukemia and multiple myeloma (147 [13.2%]), and lymphoma (141 [12.7%]) were common among adults, and leukemias (180 [42.8%]), lymphomas (66 [15.7%]), and central nervous system neoplasms (40 [9.5%]) were common among children. The median follow-up time was 37.5 (IQR, 32.6-42.3) months for adults and 25.4 (IQR, 20.9-29.9) months for children. The 5-year survival rate was 17.5% in adults and 29.7% in children.Conclusions and RelevanceDespite universal health coverage and investment in the health care system, low survival rates were reported in this study for both adults and children with cancer. These findings suggest that cancer care in refugees requires novel planning within national cancer control programs with global cooperation.
Background: Syrian refugees(SR) are said to be diagnosed at more advanced stage comparing to host nations but almost all studies lack of control arm consisting of host nations. The aim of this cross sectional retrospective study is to compare clinicopathologic features and time to reach of treatment in two groups which are SR breast cancer patients and Turkish citizens(TC) counterparts. Methods: This study was retrospective cross sectional study including breast cancer patients from monocenter in Turkey treated between 2014-2021. Patients were divided into two groups; Syrian refugees (SR) and Turkish citizens (TC). Clinicopathologic features, neoadjuvant treatment approach and time to reach treatment were investigated in two groups. Mann Whitney U test, Chi square test were used for comparision of two groups, SPSS version 25 was used for analysis and p value ≤0.05 was considered statistically significant Results: Syrian refugees ratio was 88/490 (%18), mean age at diagnosis was 45 years for SR while in TC population it was 50 years (p:0,003). There was no difference between intrinsic subtypes, Luminal subtype 45.5% to 54.4%, HER 2 positive 39.8% to 34.3%, Triple negative14,8% to 11.3% in SR and TC respectively (p>0,05) . Ratio of denovo metastatic was 20/87 (23%) in SR while in TC population it was 85/398(21.3%) (p>0,05).Upfront operation in patients who should have been offered neoadjuvan chemotheraphy was 33.3%(11/33) in SR, and it was 43/170(25.4%) in TC population (p>0,05). Median time to reach neoadjuvant chemotheraphy(ChT) in SR was 47 days (16-75) while in TC that time was 37 days(3-141) p>0,05. In upfront operated patients, median time to surgery in SR was 42 days(14-165) while in TC it was 40 days (11-134) p>0,05. In metastatic setting median time to initiate ChT in SR was 38 days (14-118) while in TC it was 41 days (11-141) p>0,05. Conclusion: SR were younger than counterparts but breast cancer subtypes were similar in both groups. Denovo metastatic ratio and neoadjuvant approach were similar between two groups showed SR could reach oncologic treatment equally to Turkish counterpart. In the aspect of treatment delay, there was no difference in time to initiate treatment between SR and TC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.